|
STXBP6 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 3.65885099995467E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.72509800783405E-11 |
| Normal-vs-Stage2 |
9.233800E-04 |
| Normal-vs-Stage3 |
4.34609999999669E-06 |
| Normal-vs-Stage4 |
1.2799999999924E-06 |
| Stage1-vs-Stage2 |
6.628400E-01 |
| Stage1-vs-Stage3 |
3.631800E-01 |
| Stage1-vs-Stage4 |
9.090600E-01 |
| Stage2-vs-Stage3 |
8.274800E-01 |
| Stage2-vs-Stage4 |
7.443400E-01 |
| Stage3-vs-Stage4 |
4.945800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.32429955890245E-10 |
| Normal-vs-AfricanAmerican |
1.409590E-04 |
| Normal-vs-Asian |
4.64489999996154E-06 |
| Caucasian-vs-AfricanAmerican |
1.172340E-02 |
| Caucasian-vs-Asian |
9.224400E-01 |
| AfricanAmerican-vs-Asian |
5.885700E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.63150000004531E-06 |
| Normal-vs-Female |
3.21020987570364E-12 |
| Male-vs-Female |
2.992000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.1601999905817E-09 |
| Normal-vs-Age(41-60Yrs) |
5.63750157667187E-11 |
| Normal-vs-Age(61-80Yrs) |
6.20999999999539E-05 |
| Normal-vs-Age(81-100Yrs) |
7.748200E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.495800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.955770E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
1.320580E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.872770E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.292500E-02 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
2.304800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
9.506400E-02 |
| Classical-VS-Follicular |
2.288400E-01 |
| Classical-VS-Other |
7.740400E-01 |
| Classical-VS-Normal |
1.37556632751057E-13 |
| Tall-VS-Follicular |
4.025800E-01 |
| Tall-VS-Other |
5.739600E-01 |
| Tall-VS-Normal |
2.239600E-02 |
| Follicular-VS-Other |
9.160800E-01 |
| Follicular-VS-Normal |
1.628210E-04 |
| Other-VS-Normal |
2.296800E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.75069999608368E-08 |
| Normal-vs-N1 |
6.614000E-04 |
| N0-vs-N1 |
6.498400E-01 |
|
|
